Sidley represented OrbiMed as one of the lead investors in Harbour BioMed (HBM) Series C financing of US$102.8 million to accelerate development of its growing portfolio. Other investors include Hudson Bay Capital Management LP, Country Garden Venture Capital, GTJA Investment Group, Octagon Capital Group, Sage Partners LLC, and Greater Bay Area Investment Fund.
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over US$14 billion in assets under management. Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19.
The deal was led by partner Ruchun Ji (M&A and Private Equity), working with senior associate Calamus Huang (M&A and Private Equity).